Law360
DOJ Kickback Concerns Extend Beyond Federal Funds
April 13, 2022
The federal government has expressed growing interest in pursuing enforcement actions focused on alleged kickbacks in the health care industry that it cannot reach with its tried-and-true lever, the Anti-Kickback Statute.
Specifically, where alleged kickback arrangements do not implicate federal funds, the U.S. Department of Justice increasingly is turning to the Travel Act and the Eliminating Kickbacks in Recovery Act, or EKRA.
Capabilities
Suggested News & Insights
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025Sidley Represents Lumexa Imaging in US$462.5 Million Initial Public OfferingDecember 10, 2025First Circuit Clarifies Application of Medicare’s “Reasonable and Necessary” Standard in FCA Cases Against Clinical LabsDecember 8, 2025Medicare Payment Policy Final Rule for Outpatient Setting Addresses Radiopharmaceuticals, Skin Substitutes, and 340B Program Key TopicsDecember 2, 2025#DrugPricing: Average Sales Price (ASP) Calculation in FocusThursday, November 20, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
